Doctolib, the prominent European healthcare platform, is launching a new scientific research project this August aimed at improving patient care pathways through artificial intelligence. The initiative, developed in collaboration with leading French scientific institutions including Inria, Inserm, and Université Paris Cité, seeks to leverage historical medical data to help healthcare professionals better anticipate health risks, optimize treatment plans, and manage complex cases. The project is scheduled to run for three years and will be conducted through a dedicated AI research laboratory.
To support this research, Doctolib will utilize demographic and health-related information from its adult users and their dependents linked to their accounts. This data may include information entered directly by patients or recorded by healthcare providers. According to the company, the information used will be pseudonymized to protect individual identities. Doctolib maintains that this initiative is designed to provide tangible benefits to the medical community by offering tools that can, for example, help identify patients at higher risk for conditions like diabetes or assist in the management of rare diseases.
While the project is framed as a public-interest research endeavor, it has drawn attention due to the sensitivity of the data involved. Doctolib has begun informing its users about the program via email. Participation is not mandatory; users who prefer not to have their data included in these research efforts can opt out by submitting a formal request through the company's research portal. The company emphasizes that choosing to opt out will have no impact on a user's access to Doctolib services or their medical care.
This development follows a period of scrutiny regarding Doctolib's data handling practices. The company has consistently stated that it complies with European regulations, including the General Data Protection Regulation, and that its services are designed with privacy and security as core priorities. As the research program begins, the focus remains on balancing the potential for medical innovation with the necessity of maintaining strict control over personal health information.